GlassScriptPhysician profile
Jennifer S Au
NPI 1851552145
$27,065.40
in general payments reported to CMS, 2019-2025
43 companies · $3,024 in 2025
The $3,024 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,938 · 2020: $133 · 2021: $670 · 2022: $1,542 · 2023: $9,939 · 2024: $1,819 · 2025: $3,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,996 · Food and Beverage: $5,711 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,995.50 |
| Food and Beverage | $5,710.52 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10,472.77 | 2019-2025 | |
| Genentech USA, INC. | $8,190.00 | 2023 | |
| Abbvie INC. | $1,903.73 | 2021-2025 | Mavyret, Linzess, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,040.18 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Astrazeneca Pharmaceuticals LP | $897.50 | 2019-2025 | |
| Janssen Biotech, INC. | $680.37 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $666.90 | 2021-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $361.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $339.84 | 2022-2025 | Dupixent |
| Genzyme Corporation | $323.54 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $311.64 | 2022-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $270.70 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $265.42 | 2021-2025 | Dificid, Prevymis, Zinplava |
| Eisai INC. | $118.96 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $117.62 | 2020 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $111.67 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $101.03 | 2024-2025 | Omvoh, Olumiant, Zepbound |
| Novo Nordisk INC | $100.70 | 2025 | Wegovy |
| Boston Scientific Corporation | $90.61 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Celltrion USA INC. | $87.51 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $64.99 | 2024-2025 | |
| Vivus LLC | $63.09 | 2022-2024 | Qsymia |
| Pfizer INC. | $47.98 | 2022 | |
| Daiichi Sankyo INC. | $40.62 | 2022-2024 | Injectafer |
| Redhill Biopharma INC. | $39.37 | 2021-2024 | Talicia |
| Ardelyx, INC. | $36.51 | 2023-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $35.93 | 2024-2025 | Rebyota |
| Kiniksa Pharmaceuticals, LTD. | $35.47 | 2022 | |
| Braintree Laboratories, INC. | $30.08 | 2024 | Suflave, Sutab |
| Veloxis Pharmaceuticals, INC. | $23.74 | 2024 | Envarsus |
| Orphalan INC | $21.66 | 2023 | Cuvrior |
| Ironwood Pharmaceuticals, INC | $19.73 | 2024 | |
| Csl Behring | $19.68 | 2021 | |
| Steris Corporation | $18.99 | 2025 | |
| Qol Medical, LLC | $17.22 | 2025 | Sucraid |
| Exelixis INC. | $17.22 | 2025 | Cabometyx |
| Cook Medical LLC | $15.42 | 2020 | |
| Glaxosmithkline, LLC. | $14.04 | 2019 | |
| Eurofins Viracor, LLC | $13.93 | 2025 | |
| Neurelis, INC. | $13.02 | 2021 | |
| Exact Sciences Corporation | $12.75 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $11.92 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Au listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.